A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Ascending KVA12123 doses given as monotherapy by intravenous administration every 2 weeks of each 6-week cycle.

Ascending KVA12123 doses given by intravenous administration every 2 weeks of each 6-week cycle in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.

KVA12123 administered at the RP2D by intravenous administration every 2 weeks of each 6 week cycle.

KVA12123 administered at the RP2D by intravenous administration every 2 weeks in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.